Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rocuronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.99 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.58 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.58 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rocuronium SCHEMBL1036090 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL6067603 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL3835255 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL3986752 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL3986751 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL41320 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL6067600 | 1.00 | KCNH2 (0.99) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10589679 | 0.99 | KCNH2 (0.97) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10589682 | 0.99 | KCNH2 (0.97) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 | |
| Rocuronium SCHEMBL3823993 | 0.99 | KCNH2 (1.00) | KCNH2AGTR1SLC22A2SLC47A2SLC47A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372302-A1 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230149390-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20210308124-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021102328-A1 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-2118096-B1 | PURIFICATION PROCESS COMPRISING DISSOLVING AN ORGANIC COMPOUND IN CARBONATED WATER AND FREEZE-DRYING | TEXCONTOR ETS (LI) | 2015-03-04 | — | — | EP | disclosed |
| EP-1828221-B2 | PROCESS FOR THE PREPARATION OF PURE ROCURONIUM BROMIDE | SICOR INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8242265-B2 | Purification process comprising dissolving an organic compound in carbonated water and freeze-drying | TEXCONTOR ETABLISSEMENT (LI) | 2012-08-14 | — | — | US | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20070117975-A1 | Processes for the synthesis of rocuronium bromide | SICOR, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117975-A1 | Processes for the synthesis of rocuronium bromide | SICOR, INC. | 2007-05-24 | — | — | US | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060058275-A1 | Processes for preparing stabilized, highly pure rocuronium bromide | CHEMAGIS LTD. (IL) | 2006-03-16 | — | — | US | disclosed |
| US-20060058276-A1 | Processes for the preparation and purification of rocuronium bromide | CHEMAGIS LTD. (IL) | 2006-03-16 | — | — | US | disclosed |
| US-20050159398-A1 | Processes for the preparation of rocuronium bromide and intermediates thereof | WAVELENGTH ENTERPRISES LTD (IL) | 2005-07-21 | — | — | US | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-0287150-B1 | NOVEL 2 BETA-MORPHOLINO-ANDROSTANE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | AKZO N.V. (NL) | 1992-08-19 | — | — | EP | disclosed |
| US-4894369-A | Novel 2β-morpholino-androstane derivatives | AKZO N.V. (NL) | 1990-01-16 | — | — | US | disclosed |
| EP-0287150-A1 | Novel 2 beta-morpholino-androstane derivatives and processes for their preparation | AKZO N.V. (NL) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372302-A1 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | ADRB2, OPRM1, ADRB1 | KCNH2 391/4885AGTR1 157/4885SLC22A2 1010/4885 |
| US-20210308124-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | OPRD1, CHRNA1, CHRNE | KCNH2 211/4885AGTR1 229/4885SLC22A2 3628/4885 |
| US-20060058275-A1 | Processes for preparing stabilized, highly pure rocuronium bromide | CHRNA5, FASTKD5, CROCC | KCNH2 250/4885AGTR1 4067/4885SLC22A2 3875/4885 |
| US-20230149390-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | OPRD1, OPRM1, CHRNA1 | KCNH2 283/4885AGTR1 211/4885SLC22A2 2533/4885 |
| US-20050159398-A1 | Processes for the preparation of rocuronium bromide and intermediates thereof | HSD17B7, MUSK, CPT1B | KCNH2 1010/4885AGTR1 1555/4885SLC22A2 3475/4885 |
| US-20060058276-A1 | Processes for the preparation and purification of rocuronium bromide | CHRNE, CHRNB1, CHRNA5 | KCNH2 449/4885AGTR1 2937/4885SLC22A2 3637/4885 |
| US-20070117975-A1 | Processes for the synthesis of rocuronium bromide | HSD17B7, HSD3B2, HSD3B1 | KCNH2 1692/4885AGTR1 2139/4885SLC22A2 3883/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | KCNH2 4861/4885AGTR1 241/4885SLC22A2 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.